SOURCE-LINKED INTELLIGENCE

Drug REpurposing with Artificial intelligence for Muscular disorderS

CORDIS · observation · Publication date unknown

Drug REpurposing with Artificial intelligence for Muscular disorderS According to World Health Organization, to date, fewer than 6% of rare diseases (RDs) have an approved treatment option. In the light of this observation, it appears crucial to develop disruptive approaches that allow to find treatments for multiple RDs. To achieve this goal, DREAMS will start from 5 rare neuromuscular disorders (NMD) that share common pathophysiological characteristics related to dysfunctions of autophagy and desmin disorganization. Using skeletal muscle cells derived from induced pluripotent stem cells (skMC-iPSC), DREAMS will i) identify shared biomarkers of the 5 diseases and ii) perform a high throughput drug screen on all 5 diseases. Through a first Artificial Intelligence (AI) based solution, the output of the drug screening will be used to find drug targets shared between the diseases. A second AI based solution will

Read original source ↗ Open in workspace

recordType

award

status

SIGNED

region

EU

value

6952110

unit

EUR